Shuqi Wang

Dr. Shuqi Wang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
KDKimberley Doucette
Kimberley Doucette
MPMary‐Elizabeth Percival
Mary‐Elizabeth Percival
LWLacey Williams
Lacey Williams
AKAdrese Kandahari
Adrese Kandahari
ATAllison Taylor
Allison Taylor
CLCatherine Lai
Catherine Lai

25 August 2021 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
NBNoa Biran
Noa Biran
EPElli Gourna Paleoudis
Elli Gourna Paleoudis
RFRena Feinman
Rena Feinman
David H. VesoleDavid H. Vesole
David H. Vesole
JZJoshua Zenreich
Joshua Zenreich
DSDavid S. Siegel
David S. Siegel
Patients with high-risk multiple myeloma (hrMM) relapse after autologous stem cell transplantation (ASCT) with a median progression free survival (PFS) of 8-14 months without lenalidomide maintenance and 24-39 months with lenalidomide maintenance. We hypothesized that Pembro-Rd will prolong PFS post-ASCT in patients with hrMM compared to historical controls. This Phase II study enrolled hrMM patients with primary objective to assess the efficacy of the combination of Pembro-Rd for a total of 2 cycles and then an additional 2 cycles without dexamethasone. There were 12 evaluable subjects, as enrollment was stopped after an FDA hold. With a median follow-up of 50.7 months, the median PFS was 27.7 months. The PFS rates at years 1 and 2 are 90.9% and 63.6%, respectively. The most common adverse events were neutropenia (grade 1-3), cough, diarrhea and constipation, all grade 1 or 2. The PFS rate with fixed duration therapy was comparable to that seen with continuous dose lenalidomide, potentially offering a new post-ASCT therapeutic strategy.

1 November 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
GAGhassan Al-Shbool
Ghassan Al-Shbool
HLHira Latif
Hira Latif
SFSaira Farid
Saira Farid
SWShuqi Wang
Shuqi Wang
JAJaeil Ahn
Jaeil Ahn
CKChul Kim
Chul Kim
Clinical trials play a crucial role in shaping the practice of medicine. Nonreporting of clinical trial results affects the validity of the literature and can negatively affect patient care. Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.1 Studies assessing reporting of clinical trial results in thoracic oncology are lacking. We sought to investigate the publication rate among registered lung cancer clinical trials.

23 May 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
SWShuqi Wang
Shuqi Wang
SWSamuel Y S Wong
Samuel Y S Wong
BYBenjamin H K Yip
Benjamin H K Yip
ELEric Kam-Pui Lee
Eric Kam-Pui Lee
Aims: This study aimed to establish an outcome-derived threshold for central blood pressure (cBP) and evaluate its clinical utility in stratifying cardiovascular (CVD) risk. Methods and results: A retrospective cohort study of 34 289 adults without prior CVD was conducted using the UK Biobank dataset. The primary endpoint was a composite of cardiovascular mortality and non-fatal cardiovascular events. Diagnostic threshold for cBP was developed by bootstrap and approximation methods, based on the current brachial BP. Cox regression models were employed to evaluate the clinical utility of diagnostic thresholds for cBP in predicting in CVD. A diagnostic threshold of 135 mmHg for central systolic blood pressure (SBP) corresponded to the threshold of 140 mmHg for brachial SBP. Simultaneous assessment of brachial and central SBP configurated following categories: brachial and central normotension (49.84%), isolated brachial hypertension (2.23%), isolated central hypertension (3.65%) and concordant brachial and central hypertension (44.28%). Compared with concordant normotension, hazard ratios for cardiovascular events were 0.81 (0.45, 1.44) for isolated brachial hypertension, 1.70 (1.23, 2.35) for isolated central hypertension and 1.51 (1.30, 1.76) for concordant hypertension. The inclusion of cBP improved model fit and discrimination for predicting CVD beyond brachial BP alone. Conclusion: This study established a diagnostic threshold of 135 mmHg for central SBP. Individuals with central HT exhibited elevated risks of CVD, regardless of brachial HT status. Incorporating central BP enhanced the prediction of CVD risk beyond traditional BP measurement alone.

14 February 2025 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
ELEric Kam-Pui Lee
Eric Kam-Pui Lee
SWShuqi Wang
Shuqi Wang
BYBenjamin Hon-Kei Yip
Benjamin Hon-Kei Yip
EYEsther Yee-Tak Yu
Esther Yee-Tak Yu
SLShuk-Yun Leung
Shuk-Yun Leung
SWSamuel Wong
Samuel Wong
This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.

1 January 2022 in Statistics and Its Interface
Verified
Journal Article
Closed access
PDF file
BZBingsong Zhang
Bingsong Zhang
SWShuqi Wang
Shuqi Wang
XMXiaohan Mei
Xiaohan Mei
YHYue Han
Yue Han
RWRunqiu Wang
Runqiu Wang
RFRuzong Fan
Ruzong Fan
International Press of Boston - publishers of scholarly mathematical and scientific journals and books